Research programme: anticancer therapeutics - Tri-Institutional Therapeutics Discovery Institute/Takeda

Drug Profile

Research programme: anticancer therapeutics - Tri-Institutional Therapeutics Discovery Institute/Takeda

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Takeda; Tri-Institutional Therapeutics Discovery Institute
  • Developer Takeda
  • Class Antibodies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Jun 2016 Takeda and Tri-Institutional Therapeutics Discovery Institute expand their collaboration to co-develop antibody based therapeutics in USA for Cancer and Undefined indications
  • 01 Oct 2013 Takeda and Tri-Institutional Therapeutics Discovery Institute agree to co-develop small molecule therapeutics in USA for Cancer and Undefined indications
  • 01 Oct 2013 Early research in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top